Incyte Corp (INCY)

Add to Watchlists
Create an Alert
Quickflows
68.96 -4.09  -5.60% NASDAQ Mar 27, 20:00 Delayed 2m USD
View Full Chart
Price Chart
View All Key Stats

Key Stats

View All INCY News

News

View All Events

Events

Date Type Description
04/30/2020 08:00 EDT Misc Incyte Corp First Quarter Earnings Conference Call in 2020
04/30/2020 Earnings Incyte Corp First Quarter Earnings in 2020 Release
02/13/2020 08:00 EST Misc Incyte Corp Fourth Quarter Earnings Conference Call for 2019
02/13/2020 07:00 EST Earnings Incyte Corp Fourth Quarter Earnings Results for 2019
02/13/2020 Misc Incyte Corp Annual Report for 2019
10/29/2019 08:00 EDT Misc Incyte Corp Third Quarter Earnings Conference Call for 2019
10/29/2019 07:00 EDT Earnings Incyte Corp Third Quarter Earnings Results for 2019
07/30/2019 08:00 EDT Misc Incyte Corp Second Quarter Earnings Conference Call in 2019
07/30/2019 Earnings Incyte Corp Second Quarter Earnings in 2019 Release
04/30/2019 08:00 EDT Misc Incyte Corp First Quarter Earnings Conference Call in 2019
View All Performance Charts

Total Returns Comparison

Fundamentals

Income Statement View Statement

Revenue (TTM) 2.159B
Total Expenses (TTM) 1.737B
Net Income (TTM) 446.91M

Balance Sheet View Statement

Total Assets (Quarterly) 3.427B
Total Liabilities (Quarterly) 828.34M
Shareholders Equity (Quarterly) 2.598B

Cash Flow Statement View Statement

Cash from Operations (TTM) 710.66M
Cash from Investing (TTM) -87.45M
Cash from Financing (TTM) 45.71M

Ratings & Reports

Advertisement
Edit

Profile

  • URL: https://www.incyte.com
  • Investor Relations URL: http://www.incyte.com/ir/investor-overview.aspx
  • HQ State/Province: Delaware
  • Sector: Healthcare
  • Industry: Biotechnology
  • Equity Style: Mid Cap/Growth
  • Next Earnings Release: Apr. 30, 2020
  • Last Earnings Release: Feb. 13, 2020
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: N/A
  • Description: Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant, which Eli Lilly licenses, and oncology drug Iclusig for chronic myeloid leukemia. Incyte's pipeline includes a broad array of oncology and autoimmune programs.

Analyst Coverage

Consensus Recommendations
Buy Recommendations Upgrade
Outperform Recommendations Upgrade
Hold Recommendations Upgrade
Underperform Recommendations Upgrade
Sell Recommendations Upgrade
Consensus Recommendation Upgrade
Consensus Rating Upgrade
Target Price
Price 68.96
Price Target Upgrade
Price Target Upside (Daily) Upgrade

Top Fund Holders

Symbol Name Weighting
FBT First Trust NYSE Arca Biotech ETF 3.53%
ARKG ARK Genomic Revolution ETF 2.73%
HQH Tekla Healthcare Investors 2.50%
IBB iShares Nasdaq Biotechnology ETF 2.15%
SCGVX Sands Capital Global Growth Inv 2.06%
VGHCX Vanguard Health Care Inv 1.90%
XBI SPDR® S&P Biotech ETF 1.65%
ATL1635 Renaissance Global Health Care Class F 1.57%
FGSCX Federated MDT Mid Cap Growth C 1.55%
RPG Invesco S&P 500® Pure Growth ETF 1.55%
SWHFX Schwab Health Care 1.36%
FBIOX Fidelity® Select Biotechnology 1.18%

Comparables

Edit
LLY Eli Lilly and Co
NOVN Novan Inc
REGN Regeneron Pharmaceuticals Inc
ALXN Alexion Pharmaceuticals Inc
GILD Gilead Sciences Inc

Other Resources

Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.

Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.